Information Provided By: 
Fly News Breaks for July 2, 2019
VCYT
Jul 2, 2019 | 05:12 EDT
Needham analyst Stephen Unger started Veracyte with a Buy rating and $33 price target. The company has "significant potential for meaningful" long-term revenue growth as its advanced diagnostic tests that improve patient outcomes, while also reducing diagnostic costs, commercializes, Unger tells investors in a research note. The analyst believes Veracyte's Afirma Gene Expression Classifier is a well established test used by U.S. physicians to improve the diagnosis of thyroid nodules.
News For VCYT From the Last 2 Days
There are no results for your query VCYT
